Drugs

Hanna Foster/LinkedIn

Dec 21, 2024, 10:38

Hanna Foster: Market cap and Revenue of Cancer NGS Drugs providers in 2024

Hanna Foster, Scientific Product Sales Manager at Quadratech DiagnosticsLtd, shared on LinkedIn:

“Market cap and Revenue of Cancer NGS Drugs providers in 2024.

– Market cap is the total market value of a publicly traded company’s outstanding shares

– Revenue is the total income that a company generates from its business activities

– P/S ratio (price/sales ratio, revenue multiples) is calculated by dividing company’s market cap by revenue and provides a glimpse into how stock market values its future growth and earnings potential

NGS testing providers by P/S ratio (market cap / revenue):

1. Natera: 14.5 ($22.2B / $1.53B)
2. Tempus: 9.6 ($6.13B / $0.64B)
3. Veracyte: 7.7 ($3.27B / $0.42B)
4. Guardant Health: 6.2 ($4.3B / $0.69B)
5. Adaptive Biotechnologies: 5.4 ($0.96B / $0.17B)
6. Exact Sciences: 4.1 ($11.17B / $2.69B)
7. NeoGenomics: 3.5 ($2.25B / $0.64B)
8. SOPHiA Genetics: 3.4 ($0.22B / $0.06B)
9. Personalis: 3.1 ($0.27B / $0.09B)
10. Myriad Genetics: 1.5 ($1.25B / $0.82B)

1. Natera’s market cap of ~$22B is likely driven by its leadership in oncology MRD market ($20B TAM in the US), with growing adoption of Signatera in surveillance setting and lower COGS of subsequent tests

2. Tempus has a market cap of ~$6B in its eventful first year as a public company (IPO in Jun 2024 & acquisition of Ambry Genetics in Nov 2024), suggesting investors’ confidence in its AI-enabled data platform and diagnostic tests

3. Veracyte’s market cap nearly doubled since Aug 2024, with company posting record revenues in Q3 2024 and investing in new technologies, with acquisition of C2i Genomics MRD platform earlier in the year

Should we expect any changes in 2025? Any companies to omit / add to the list?

Thanks to Joanna Sadowska, for inspiration.”

Hanna Foster